ASP Isotopes Inc.: files Regulation FD disclosure on merger

What happened

• The filing states that ASP Isotopes Inc. previously entered into an Agreement and Plan of Merger on Jun 25, 2026 among ENDRA Life Sciences Inc., Noble Africa LLC, Renergen Limited, ASP Isotopes Inc., and Kruger Merger Sub LLC.
• On Oct 2, 2026, ENDRA filed a Registration Statement on Form S-4 relating to the proposed merger (the “Merger”), which contains information about Renergen. The filing says the Registration Statement is incorporated by reference into ASP Isotopes’ Form 8-K.

Key details

• Merger Agreement date: Jun 25, 2026.
• Parties named: ENDRA Life Sciences Inc.; Noble Africa LLC (direct, wholly-owned subsidiary of ASP Isotopes Inc.); Renergen Limited (direct, wholly-owned subsidiary of ASP Isotopes Inc.); Kruger Merger Sub LLC (direct, wholly-owned subsidiary of ENDRA).
• Transaction structure described: Merger Sub will merge with and into Noble Africa, with Noble Africa surviving as a direct wholly-owned subsidiary of ENDRA.
• ENDRA may file amendments and additional related filings with the SEC; those filings will be available at www.sec.gov.

Why it may matter

• Item reported: Item 7.01, Regulation FD Disclosure. This item covers public disclosure of the Registration Statement on Form S-4 filed by ENDRA on Oct 2, 2026 that relates to the proposed merger and that includes information about Renergen.
  A filing does not show why the insider traded or why the company acted.